June 26th, the high end of the exchange of biotechnology will be held in beijing. The new development of tumor targeted therapy in China and cuba. Peking University Cancer Hospital Professor Zhang Xiaodong introduced the just concluded annual meeting of the American Society of Clinical Oncology (ASCO Conference) on esophageal cancer research report. The clinical study of the treatment of patients with advanced esophageal squamous cell carcinoma treated with the combination of rituximab and paclitaxel and cisplatin in patients with advanced esophageal squamous cell carcinoma showed that the combination therapy can benefit patients.

The nimotuzumab combined with paclitaxel alcohol and cisplatin in the first-line treatment of esophageal squamous cell carcinoma, single center, prospective clinical research, patient tissue typing for advanced esophageal squamous cell carcinoma, lesions were measured before, did not receive radiotherapy and chemotherapy in the treatment of. Dosing regimen: Cisplatin 60 mg / m2, paclitaxel 175 mg / m2; every 21 days for a period of at least 2 cycles. Intravenous injection of 200 mg per week. The results showed that the treatment efficiency could be increased by (up to 55%) compared with chemotherapy alone, with the addition of rituximab, the treatment efficiency was increased by 20% (from 35% to). At the same time, the combination regimen was well tolerated, with no serious adverse reactions.

Esophageal cancer is one of the most malignant tumors with high incidence in China, due to the race and the causes of such differences, differing of esophageal cancer in China characteristics of Europe and the United States (lower thoracic esophagus and adenocarcinoma), in the middle, squamous cell carcinoma for, the proportion of squamous cell carcinoma of up to more than 90%. This difference makes the relevant guidelines formulated by foreign countries is not entirely applicable to patients in china. Although the clinical treatment of esophageal cancer has made remarkable progress, but the overall survival rate of 5 years is still less than 20%. One of the reasons for the low cure rate of esophageal cancer is mild symptoms of early esophageal cancer, it is not easy to find that about 80% of patients with newly diagnosed. Zhang Xiaodong said that there is no standard for advanced esophageal squamous cell carcinoma of the drug treatment program. Most of the existing combined chemotherapy is by single drug treatment of esophageal carcinoma and effective medicines., platinum containing cisplatin (DDP) - fluorouracil (5-FU), DDP- paclitaxel (PTX) and DDP- leucovorin calcium (CF) / 5-FU was recognized as a first-line treatment for esophageal cancer of the basic scheme. With the development of molecular biological mechanism in the process of carcinogenesis, development and metastasis, the emergence of molecular targeted drugs has brought new hope for the treatment of esophageal cancer. Clinical study suggests that the combination of synchronous radiotherapy and chemotherapy and molecular targeted therapy can improve the remission rate of esophageal cancer, and effectively improve the survival rate of patients. At present, epidermal growth factor receptor (EGFR) for target of esophageal cancer therapeutics has two kinds, a kind of is role in receptor intracellular region of small molecule tyrosine kinase inhibitor (TKI), mainly including gefitinib Nepal and erlotinib erlotinib and other; another kind is effect to the extracellular domain of receptor monoclonal antibody (mAb), including cetuximab cetuximab, panitumumab, Nigeria properly natalizumab and Ma trastuzumab monoclonal antibody.

Experts said that at present the treatment of esophageal cancer is still in operation, but overall curative effect still is not satisfied, to explore new mode of treatment of research and development of new drugs is imperative; target to the birth of drug to improve the treatment of esophageal cancer provides a new direction.